Evidence map›Paper›PMID 26362250›Full record

ArticleHuman molecular genetics2015

miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo.

Pascal Y Smith, Julia Hernandez-Rapp, Francis Jolivette, Cynthia Lecours, Kanchan Bisht, Claudia Goupil, Veronique Dorval, Sepideh Parsi, Françoise Morin, Emmanuel Planel and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 4 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

149 citing papers in PubMed, 4 syntheses or guidelines pooled it, 234 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. MicroRNAs in neurodegenerative diseases: from molecular mechanisms to clinical biomarkers, detection methods and therapeutic strategies-advances and challenges.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  18. Review
  19. Review
  20. Review

89 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 3 countries.

Pascal Y SmithAxe Neurosciences, Centre de Recherche du CHU de Québec, CHUL, Québec, QC, Canada G1V 4G2, Département de Psychiatrie et Neurosciences.
Julia Hernandez-RappAxe Neurosciences, Centre de Recherche du CHU de Québec, CHUL, Québec, QC, Canada G1V 4G2, Département de Psychiatrie et Neurosciences.
Francis JolivetteAxe Neurosciences, Centre de Recherche du CHU de Québec, CHUL, Québec, QC, Canada G1V 4G2, Département de Psychiatrie et Neurosciences.
Cynthia LecoursAxe Neurosciences, Centre de Recherche du CHU de Québec, CHUL, Québec, QC, Canada G1V 4G2, Département de Médecine Moléculaire.
Kanchan BishtAxe Neurosciences, Centre de Recherche du CHU de Québec, CHUL, Québec, QC, Canada G1V 4G2, Département de Médecine Moléculaire.
Claudia GoupilAxe Neurosciences, Centre de Recherche du CHU de Québec, CHUL, Québec, QC, Canada G1V 4G2, Département de Psychiatrie et Neurosciences.
Veronique DorvalAxe Neurosciences, Centre de Recherche du CHU de Québec, CHUL, Québec, QC, Canada G1V 4G2, Département de Psychiatrie et Neurosciences.
Sepideh ParsiAxe Neurosciences, Centre de Recherche du CHU de Québec, CHUL, Québec, QC, Canada G1V 4G2, Département de Psychiatrie et Neurosciences.
Françoise MorinAxe Neurosciences, Centre de Recherche du CHU de Québec, CHUL, Québec, QC, Canada G1V 4G2, Département de Psychiatrie et Neurosciences.
Emmanuel PlanelAxe Neurosciences, Centre de Recherche du CHU de Québec, CHUL, Québec, QC, Canada G1V 4G2, Département de Psychiatrie et Neurosciences.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA.
Francisco-Jose Fernandez-GomezFaculté de Médecine, Université de Lille, UDSL, Lille F-59045, France and UMR-S 1172, Alzheimer and Tauopathies, Inserm, Lille F-59045, France.
Nicolas SergeantFaculté de Médecine, Université de Lille, UDSL, Lille F-59045, France and UMR-S 1172, Alzheimer and Tauopathies, Inserm, Lille F-59045, France.
Luc BuéeFaculté de Médecine, Université de Lille, UDSL, Lille F-59045, France and UMR-S 1172, Alzheimer and Tauopathies, Inserm, Lille F-59045, France.
Marie-Ève TremblayAxe Neurosciences, Centre de Recherche du CHU de Québec, CHUL, Québec, QC, Canada G1V 4G2, Département de Médecine Moléculaire.
Frédéric CalonAxe Neurosciences, Centre de Recherche du CHU de Québec, CHUL, Québec, QC, Canada G1V 4G2, Faculté de Pharmacie, Université Laval, Québec, QC, Canada G1V 0A6.
Sébastien S HébertAxe Neurosciences, Centre de Recherche du CHU de Québec, CHUL, Québec, QC, Canada G1V 4G2, Département de Psychiatrie et Neurosciences, sebastien.hebert@neurosciences.ulaval.ca.
Centre hospitalier universitaire de Québec · CAInserm · FRRush University Medical Center · US

Funding

SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Risk Factors, Pathology, and Clinical Expressions of ADRF1AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2014 to 2014
$6.0M
CIHR 00892-000NIA NIH HHS P30 AG010161NIA NIH HHS P30AG10161NIA NIH HHS R01 AG015819NIA NIH HHS RF1 AG015819NIA NIH HHS RF1AG15819
6 · The paper itself

Abstract

Alzheimer's disease (AD) and related tauopathies comprise a large group of neurodegenerative diseases associated with the pathological aggregation of tau protein. While much effort has focused on understanding the function of tau, little is known about the endogenous mechanisms regulating tau metabolism in vivo and how these contribute to disease. Previously, we have shown that the microRNA (miRNA) cluster miR-132/212 is downregulated in tauopathies such as AD. Here, we report that miR-132/212 deficiency in mice leads to increased tau expression, phosphorylation and aggregation. Using reporter assays and cell-based studies, we demonstrate that miR-132 directly targets tau mRNA to regulate its expression. We identified GSK-3β and PP2B as effectors of abnormal tau phosphorylation in vivo. Deletion of miR-132/212 induced tau aggregation in mice expressing endogenous or human mutant tau, an effect associated with autophagy dysfunction. Conversely, treatment of AD mice with miR-132 mimics restored in part memory function and tau metabolism. Finally, miR-132 and miR-212 levels correlated with insoluble tau and cognitive impairment in humans. These findings support a role for miR-132/212 in the regulation of tau pathology in mice and humans and provide new alternatives for therapeutic development.

Indexed as

AnimalsCognition DisordersDisease Models, AnimalDown-RegulationGene Expression RegulationGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHumansMiceMicroRNAsPhosphorylationProtein Aggregation, PathologicalTauopathiestau ProteinsGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGSK3B protein, humanGsk3b protein, mouseMicroRNAsMIRN132 microRNA, humanMIRN132 microRNA, mouseMIRN212 microRNA, humanMIRN212 microRNA, mousetau Proteins

Identifiers

PMID26362250
PMCPMC4634376
OpenAlexW2181195518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.